JMP puts MGI at market perform

MGI Pharma, Inc. was rated at market perform by JMP Securities analyst Charles C. Duncan. The company's fourth-quarter 2005 financial results were mixed. JMP maintains its 2006 Aloxi sales estimates of $284 million, on the low end of company guidance. The analyst is skeptical of outer year growth in Aloxi sales and of the planned second-quarter launch of Dacogen. Shares of the Bloomington, Minn., biopharmaceutical company were up 80 cents, or 4.68%, at $17.90 on volume of 2,661,644 shares versus the three-month running average of 1,442,480 shares. (Nasdaq: MOGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.